Key Highlights
•
Specific combinations of blood biomarkers can predict the location and progression of Alzheimer’s disease pathology, such as amyloid in the precuneus and tau in the entorhinal cortex. This finding supports the use of simple blood tests as a cost-effective and non-invasive tool for early detection and personalized risk assessment of Alzheimer’s.
Source →
•
A machine learning model that combined a four-metabolite risk score with clinical factors accurately predicted which patients with gout would experience recurrent flares while on preventive colchicine therapy. This metabolomic signature could help doctors personalize the dose and duration of preventive medication when starting new gout treatment.
Source →
•
Cardiac amyloidosis, a condition where abnormal proteins build up in the heart, is found across the full spectrum of heart function, not just in hearts with preserved pumping ability. Combining measurements of heart pumping, muscle strain, and blood flow creates a more accurate picture for predicting patient survival than any single test alone.
Source →
•
A modified dose of the COVID-19 antiviral nirmatrelvir/ritonavir (150/100 mg once daily) was found to be safe and achieved effective drug levels in patients with severe kidney impairment, including those on dialysis. This provides a crucial treatment option for a high-risk group that was previously excluded from standard dosing due to safety concerns.
Source →
•
Adding chemotherapy to a targeted drug (aumolertinib) significantly delayed cancer progression compared to the targeted drug alone for patients with a specific type of lung cancer that also has mutations in tumor suppressor genes. This is the first prospective evidence supporting a more intensive, genotype-directed treatment approach for this molecular subgroup.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
